🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Peripheral T Cells Lymphoma (PTCL)

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949n/a1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: chidamide A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Golicitinib combined with Pomadomide Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Chidamide combined with Duvillisib Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma NCT07300514Phase 31 site📍 Shanghai Fudan University · Tests: PET-CTandct- DNAdetection, golidocitinib, Placebo Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Duvelisib, Venetoclax A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL NCT05931263Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: C-BEAM Regimen, BEAM Regimen Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy NCT07414758Phase 31 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: golidocitinib, Placebo A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162Phase 351 sites📍 Hefei📍 Hefei📍 Beijing Dizal Pharmaceuticals · Tests: Golidocitinib, Chidamide, Gemcitabine Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724Phase 26 sites📍 Kaohsiung City📍 Kaohsiung City📍 New Taipei City Great Novel Therapeutics Biotech & Medicals Corporation · Tests: Chidamide Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) NCT05976997Phase 21 site📍 Wuhan Liling Zhang · Tests: Duvelisib, Chidamide Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma NCT06909877Phase 1, Phase 21 site📍 Chengdu Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Linperlisib Combined With Chidamide in Patients With PTCL NCT06421948Phase 1, Phase 26 sites📍 Zhengzhou📍 Wuhan📍 Changsha Yanyan Liu · Tests: Linperlisib and chidamide, Linperlisib and chidamide, Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubic… Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR) NCT07253129n/a1 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Autologous Hematopoietic Stem Cell Transplantation, Allogenic stem cell transplant (ASCT) Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma NCT06561048Phase 337 sites📍 Duarte📍 Irvine📍 San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Belinostat, Pralatrexate Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048Phase 110 sites📍 Scottsdale📍 Duarte📍 Los Angeles SciTech Development, Inc. · Tests: Fenretinide Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients NCT07074457NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide), Consolidation therapy- 3 or 6 cycles of BvC(Bre… Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813Phase 1, Phase 21 site📍 Shanghai Ruijin Hospital · Tests: CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas NCT07018752Phase 1, Phase 220 sites📍 Caen📍 Clermont-Ferrand📍 Créteil The Lymphoma Academic Research Organisation · Tests: roginolisib, golcadomide, azacitidine Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) NCT07750886n/a1 site📍 Austin Natera, Inc. Polyspecific Antibodies in Lymphoproliferative T-cell Disorders NCT06495723Phase 1, Phase 28 sites📍 Caen📍 Clermont-Ferrand📍 Créteil Xenothera SAS · Tests: LIS1 Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL NCT04747236Phase 26 sites📍 Long Beach📍 New Haven📍 New York University of Virginia · Tests: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy NCT06724237Phase 3165 sites📍 Birmingham📍 Anchorage📍 Anchorage Eastern Cooperative Oncology Group · Tests: Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone… Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: EBV TCR-T AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. NCT06137144Phase 1, Phase 238 sites📍 Duarte📍 Miami📍 Atlanta AstraZeneca · Tests: AZD3470, Pembrolizumab A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma NCT07192471Phase 122 sites📍 Duarte📍 Orange📍 Stanford Kyowa Kirin, Inc. · Tests: KK2223 Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients NCT07072221NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: BCL regimen, Cohort 1 (ASCT-eligible), Cohort 2 (ASCT--ineligible) Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL NCT07372352Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Zeprumetostat, Azacitidine (AZA), Mitoxantrone Hydrochloride Liposome To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL NCT07143929Phase 11 site📍 Beijing Peking University People's Hospital · Tests: CAR-T Golidocitinib Plus CHOP in Newly Diagnosed PTCL NCT06739265Phase 1, Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Golidocitinib plus CHOP
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy